Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation, Atezolizumab, and Nab-paclitaxel in TNBC
NCT04249167Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Mayo Clinic. Primary endpoint: Safety and Feasibility of cryoablation with systemic atezolizumab/nab-paclitaxel at 5 years. Planned start Jan 2020; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04249167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249167.